Angiogenesis Antibodies

Cat. No.

AT0717

CAS No.

2517939-46-5

Zifibancimig

Synonyms: RO-7250284

Zifibancimig is a monoclonal antibody of the IgG1κ isotype, designed to target and neutralize both VEGFA (Vascular Endothelial Growth Factor A) and ANGPT2 (Angiopoietin-2). This dual specificity makes it a valuable tool for investigating the complex interplay between these two critical angiogenic factors in various pathological conditions. Zifibancimig is utilized primarily in research focused on angiogenesis, tumor growth, and vascular diseases.

Cat. No.

AT0817

CAS No.

2997627-68-4

Inlecitug

Inlecitug is a chimeric monoclonal antibody designed to target the human kinase insert domain receptor (KDR). By specifically binding to KDR, Inlecitug effectively blocks the interaction between vascular endothelial growth factor (VEGF) and KDR, subsequently inhibiting angiogenesis. This inhibition plays a crucial role in exerting antitumor activity, making Inlecitug a valuable tool for cancer research.

Cat. No.

AT1115

CAS No.

216974-75-3

Bevacizumab (PBS)

Synonyms: Anti-Human VEGF; Humanized Antibody (PBS

Bevacizumab is a humanized IgG1 monoclonal antibody that exhibits high-affinity binding to all isoforms of vascular endothelial growth factor A (VEGF-A). This targeted binding inhibits the interaction of VEGF-A with its receptors, thereby modulating angiogenesis.

Cat. No.

AT1131

CAS No.

947687-13-0

Ramucirumab (anti-VEGFR)

Ramucirumab is a recombinant human IgG1 monoclonal antibody specifically designed to target and antagonize vascular endothelial growth factor receptor 2 (VEGFR-2). By binding to the extracellular domain of VEGFR-2, Ramucirumab effectively inhibits the interaction with its natural ligands, VEGF-A, VEGF-C, and VEGF-D. This blockade disrupts the downstream signaling pathways that promote angiogenesis, making Ramucirumab a potent angiogenesis inhibitor. It is primarily utilized in the clinical management of various solid tumors, leveraging its mechanism to impair tumor vascularization and growth.

Cat. No.

AT1416

Anti-PDGFRB/CD140b Antibody (IMC-2C5)

Synonyms: IMC-2C5

IMC-2C5 is a fully human monoclonal antibody that acts as an antagonist to platelet-derived growth factor receptor beta (PDGFRβ). This antibody is designed to enhance antitumor activity and potentiate the effects of antiangiogenic agents across a diverse array of human cancers. Targeting PDGFRβ, IMC-2C5 has demonstrated efficacy in inhibiting tumor growth and angiogenesis, making it a valuable tool for cancer research and therapeutic development.

Cat. No.

AT1479

CAS No.

1296818-77-3

Nesvacumab

Nesvacumab is a fully human monoclonal antibody of the immunoglobulin G1 (IgG1) class, designed to selectively target and neutralize the Tie2 receptor ligand Angiopoietin-2 (Ang2). It exhibits high binding affinity specifically for Ang2, without interacting with Angiopoietin-1 (Ang1). This specificity makes it an ideal candidate for research focused on vascular biology and diseases associated with Ang2-mediated signaling pathways.

Cat. No.

AT1545

CAS No.

1448221-05-3

Vanucizumab

Synonyms: Anti-Human VEGFA Recombinant Antibody; RO5520985

Vanucizumab is a pioneering bispecific IgG1-like monoclonal antibody designed to concurrently inhibit the interaction of vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2) with their respective receptors. This dual blockade mechanism endows vanucizumab with potent antiangiogenic and anticancer properties, making it an essential tool for research in tumor growth and metastasis inhibition.

Cat. No.

AT1551

CAS No.

1205533-60-3

Vesencumab

Synonyms: MNRP-1685A

Vesencumab (MNRP-1685A) is an IgG1 monoclonal antibody that targets neuropilin-1 (NRP-1), a co-receptor involved in angiogenesis and the enhancement of vascular endothelial growth factor (VEGF) signaling through its association with VEGFR-2. By binding to NRP-1, Vesencumab effectively inhibits the interaction between NRP-1 and VEGFR-2, thereby exerting anti-angiogenic and anti-neoplastic effects. This antibody is particularly useful in research focused on the mechanisms of metastasis and tumor growth in solid tumors, including studies on ovarian cancer.